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In this work, with the aim of finding proteins that could serve as novel biomarkers 
for colorectal cancer (CRC), we performed a search focused on soluble proteins that 
could be involved in cancer-related processes, such as signal transduction or metastasis. 
Among the identified proteins, we propose the nucleoside diphosphate kinase A (NDK 
A or nm23-H1) as a potential candidate.
First, we performed a pre-fractionation method to obtain fractions enriched in 
soluble proteins from mucosa and tumour tissue of 10 CRC patients with lymph node 
metastases. Then, proteins were separated by two-dimensional electrophoresis (2-DE) 
and the ones found altered were analysed applying principal component analysis 
(PCA) and linear discriminant analysis (LDA). These statistical methods allowed us 
to find a group of proteins with potential utility as a panel of markers for CRC, which 
were submitted to mass spectrometry (MS) for identification. Among the identified 
proteins, we found peroxiredoxins, the oncoprotein DJ-1, the calcium binding protein 
S100A11, the tubulin-specific chaperone A (CFA), the retinoblastoma-binding protein 
4 (RBBP-4), the 14-3-3 zeta protein, an enzyme involved in the control of DNA 
methylation (AHCY) and other enzymes related to angiogenesis (PD-ECGF/TP) and 
to the metastatic potential of tumours (NDK A).
Regarding NDK A, its role in CRC metastasis is still controversial, since both 
overexpression and downregulation have been reported. In our study, it was found 
increased (4.3 times) in tumours and the graphic representation of its level in 2-DE 
gels allowed an effective separation of mucosa and tumour samples. Furthermore, the 
upregulation of NDK A was corroborated by Western blot, and, it also represented 
one of the more relevant proteins pointed out by PCA. Noticeably, preliminary results 
showed that serum NDK A levels tended to be higher in CRC patients with distant 
metastases. In conclusion, NDK A seems to be a potential biomarker for CRC.
